Welcome to Neurotech Pulse – Issue #38! This edition captures a turning point for therapeutic neurotech, with capital flooding into mental health and implantable neuromodulation at a pace the field hasn’t seen.
Mobia Medical’s $150M Nasdaq IPO, Neuralink’s sovereign backing from Oman’s OIA, BlueWind Medical’s $47.8M financing, and SonoMind’s €20M Series A headline a month where mental health indications are absorbing outsized attention from investors. MintNeuro and Motif Neurotech announced a landmark chip-supply partnership for miniaturized therapeutic BCIs.
This issue’s Case Study features Subsense — the Palo Alto startup developing an inhalable, nanoparticle-based BCI that requires no surgery whatsoever.
⚡️Neurotech Newsflash
Mobia Medical lists on Nasdaq in $150M IPO (stroke recovery neuromodulation): The company's Vivistim Paired Vagus Nerve Stimulation System — the first FDA-approved VNS device for chronic ischemic stroke — priced at $15/share on May 7 and began trading May 8 under MOBI. Roughly $93.5M of proceeds will expand the direct sales force targeting 1M+ eligible US stroke survivors. (Read more)
MintNeuro and Motif Neurotech partner to miniaturize therapeutic BCI implants (mental health neuromodulation): The May 1 partnership combines MintNeuro’s low-power neural semiconductors with Motif’s clinical-stage implant platform under a multi-year chip supply deal, targeting smaller, lower-power BCIs for psychiatric conditions. (Read more)
Cortec demonstrates first-in-human fully implantable BCI for stroke hand function (motor restoration): At INS 2026, Cortec presented data from the first human use of its fully implantable subdural cortical stimulation system, showing meaningful hand-function improvements in chronic stroke patients using simultaneous recording and stimulation. (Read More)
Neuralink receives sovereign investment from Oman Investment Authority (BCI expansion): Oman’s OIA disclosed a strategic stake in Neuralink as part of its deep-tech diversification strategy. As of January 2026, Neuralink had implanted devices in 21 patients, with Musk targeting 1,000 procedures by year-end. (Read more)
Neurosoft Bioelectronics closes oversubscribed $7.5M seed for soft BCI platform (clinical-stage implants): Led by Skybound Venture Capital, the May 20 round brings total funding to $20M+. Neurosoft’s stretchable electrode arrays minimize tissue response by flexing with the brain’s surface, with active trials in the US and Europe. (Read more)
Epineuron Receives FDA 510(k) Clearance for Evala® Nerve Stimulator: Epineuron has received FDA 510(k) clearance for its Evala® Nerve Stimulator — a handheld bioelectronic device designed to help surgeons rapidly identify and evaluate nerves during surgery. The approval marks another step forward for peripheral nerve care and highlights the growing role of bioelectronic medicine in improving surgical precision and nerve regeneration outcomes. (Read More)
💰Notable Funding
BlueWind Medical raises $47.8M to commercialize its Revi bladder neuromodulation system: Revi is an implantable tibial nerve stimulator for overactive bladder requiring no external components. Proceeds fund US commercial expansion in a high-prevalence condition with limited existing options. (Read more)
SonoMind raises €20M Series A for non-invasive focused ultrasound targeting treatment-resistant depression: The round funds clinical development of SonoMind’s transcranial focused ultrasound platform, which reaches deep brain circuits without surgery — targeting the ~30% of depression patients who don’t respond to first-line treatments. (Read more)
Ampa raises ~$17M oversubscribed round to expand portable TMS platform for depression: Backed by Tim Ferriss (whose public endorsement amplified the raise), proceeds fund at-home and point-of-care rollout of Ampa’s fast-acting TMS device — a direct challenge to the clinic-only TMS model. (Read more)
EBT Medical and NinaMED secure $13.75M to advance NiNA System for overactive bladder: The joint financing supports commercialization of the licensed NiNA tibial nerve modulation platform, signaling that bladder indications are now attracting multiple investors simultaneously alongside neurological targets. (Read more)
Nexstim secures €5M from Eiffel and Brainlab to advance TMS navigation platform: Brainlab’s participation — from a company dominant in surgical navigation — suggests downstream interest in integrating TMS neuromodulation into surgical planning workflows. (Read More)
Neurosoft Bioelectronics awarded Swiss federal grant alongside its seed round: The government grant supports Neurosoft’s ongoing clinical trials and R&D in Switzerland, a growing European neurotech funding hub, complementing its private capital raise. (Read more)
🧠 Neurotech Trends
BCI funding reaches a new structural scale as sovereign and institutional capital enters the field: BCI companies raised ~$1.73B across 8 deals in the past 12 months — 76% of all neurotech capital by dollar value — with average deal size at $216M. OIA’s Neuralink investment joins prior sovereign backers from Qatar and UAE, signaling BCIs are becoming a geopolitical infrastructure bet, not just a venture category. (Read more)
Mental health neuromodulation absorbs a disproportionate share of May 2026 capital, signaling a category shift: Over $100M in disclosed financing (SonoMind, Ampa, EBT/NinaMED, Nexstim) — excluding Mobia’s IPO — flowed into mental health or bladder neuromodulation in early May alone. Investors are backing depression, OAB, and anxiety targets with conviction previously reserved for paralysis and motor restoration. (Read more)
Neuromodulation leads by deal count; BCIs dominate by capital — a bifurcated market structure is forming: Neuromodulation devices account for 45.5% of disclosed deals but a small fraction of dollars; BCIs took 76% of capital from just 8 deals. Founders building differentiated neuromodulation without a path to platform-scale BCI face a narrowing fundraising window. (Read more)
📘 Neurotech Article
Foundation model decodes brain activity across individuals: Researchers introduced a large-scale neural foundation model trained on multimodal brain datasets to generalize across subjects and tasks, improving brain signal interpretation without heavy subject-specific calibration. The work could accelerate scalable BCIs and more adaptable neurotechnology systems. (Read More)
Blood biomarkers show promise for early Parkinson’s detection: A new study identified plasma biomarkers linked to early Parkinson’s progression and cognitive decline, strengthening the case for minimally invasive diagnostics before severe symptoms emerge. The findings could support earlier intervention and personalized treatment pathways. (Read More)
EEG signatures linked to depression severity and treatment response: Researchers found distinct electrophysiological patterns associated with depressive symptom severity and antidepressant response, reinforcing EEG’s potential as an objective biomarker in psychiatry. The study advances efforts toward precision mental health diagnostics. (Read More)
High-resolution brain mapping reveals new principles of neural organization: Scientists used large-scale neural recording and computational analysis to uncover previously hidden organizational patterns in the human brain, offering deeper insight into how cognition and behavior emerge from distributed neural networks. The findings may inform next-generation neurotechnologies and brain-inspired AI. (Read More)
🌐 Neurotech Edu. and Events
Active Implantable Medical Devices (AIMD) Workshop 2026
📅 Date: June 4–5, 2026 | 📍 Delft, Netherlands
Why Attend the Event? Focuses on next-generation implantable medical devices, bioelectronics, neural interfaces, and regulatory pathways shaping future neurotechnology innovation.
Link to register: Register HereClinical TMS Society Annual Meeting 2026
📅 Date: June 4–6, 2026 | 📍 Boston, Massachusetts
Why Attend the Event? Brings together clinicians, researchers, and industry leaders exploring transcranial magnetic stimulation (TMS), neuromodulation therapies, and advancements in psychiatric and neurological care.
Link to register: Register HerePrecision Neuroscience Conference 2026
📅 Date: June 10–12, 2026 | 📍 Aarhus, Denmark
Why Attend the Event? Highlights emerging research in precision neuroscience, neuroimaging, computational neuroscience, biomarkers, and data-driven approaches for personalized brain health.
Link to register: Register here🎬Case Studies
🎬 Case Study Spotlight: Subsense – Delivering Brain-Computer Interfaces Without a Single Incision.
What if the next brain-computer interface wasn’t implanted — it was inhaled? That is Subsense’s founding premise. While every other BCI company today either opens the skull or threads a catheter through a blood vessel, the Palo Alto startup is pursuing a radically different path: engineered nanoparticles, delivered via nasal spray, that cross the blood–brain barrier to both sense and stimulate neural activity. No incision. No implant.
Overview:
Subsense is developing the first nanoparticle-based, non-surgical bidirectional BCI. The system pairs two categories of engineered nanoparticles — plasmonic nanoparticles for signal sensing and magnetoelectric nanoparticles for stimulation — with specialized hardware and neural decoding software. Delivery is non-invasive: particles are administered via nasal spray and engineered to cross the blood–brain barrier, reaching target neural circuits without surgery. The company was co-founded by CEO Tetiana Aleksandrova and investor Artem Sokolov, and operates a dedicated neuroengineering laboratory in Palo Alto with academic partnerships at UC Santa Cruz and ETH Zurich.
Use Case Highlights:
Neurodegeneration: Targeted stimulation and signal monitoring for Parkinson’s disease, Alzheimer’s, and epilepsy.
Recovery & Rehabilitation: Stroke recovery, motor rehabilitation, and chronic pain management via non-invasive neural modulation.
Mental Health: Depression treatment through circuit-level stimulation without surgical intervention.
Future Horizons: Sensory restoration, inner-speech decoding, and direct AI-to-brain interfaces — the company’s longer-range “moonshot” targets.
Target Audience:
Neurologists, movement disorder specialists, and rehabilitation clinicians managing Parkinson’s, epilepsy, stroke recovery, and chronic pain
Neuroscience and biomedical researchers exploring non-invasive neural interface technologies and nanoparticle delivery mechanisms
Medical device investors and venture capital firms tracking pre-clinical BCI platforms with large therapeutic TAMs
Regulatory and clinical development teams evaluating novel non-surgical pathways to FDA and EMA approval
Pharmaceutical and biotech companies exploring combination approaches that pair drug delivery with neural modulation.
Key Partnerships:
Subsense emerged from stealth in February 2025 with a $17M seed round led by Golden Falcon Capital, followed by a $10M extension in December 2025, bringing total funding to $27M. Golden Falcon has led every round to date — an unusually high-conviction signal at this pre-clinical stage. Academic validation partnerships with UC Santa Cruz and ETH Zurich are supporting early proof-of-concept work in nanoparticle delivery mechanisms and therapeutic applications.
Animal studies began in late 2025, with a proof-of-concept milestone targeted for late 2026: demonstrating reading, stimulation, and symptom treatment in mouse models of Parkinson’s or epilepsy. Pilot human clinical trials are projected for 2027. Biocompatibility and safety assessments are expected to complete by 2028, with regulatory submission to follow and approval targeted around 2031.
Leadership Team:
Subsense is led by Tetiana Aleksandrova (Co-Founder & CEO), a neurotech entrepreneur who has positioned the company at the intersection of materials science, neuroscience, and clinical translation. Co-founder Artem Sokolov, founder of Golden Falcon Capital, brings venture and strategic capital experience alongside deep conviction in the nanoparticle BCI thesis — having backed the company at every funding stage. The R&D team spans nanoparticle engineering, neural signal acquisition, machine learning, and regulatory strategy, with a dedicated Director of R&D Systems appointed in December 2025.
For more information, visit subsense-bci.com.
🌟 Neurotech Pulse Special Edition: Call for Contributions!
Calling all researchers and writers! Want to showcase your work in our upcoming Neurotech Insights edition? Reach over 5,000+ neurotech enthusiasts by sharing your innovative research. Submit your details and work to collaboration@anthriq.com
❤️ Join us on Discord.
Thanks for reading Neurotech Pulse! Subscribe for free to receive new posts.